Precipio (PRPO) Market and Corporate Developments – 20 October 2026
Market Performance
- Current trading price: USD 22.36.
- 24‑hour change (ending 06:17 PM CET): +2.41 %.
- Volume traded in last 24 hours: USD 518,800.
- Shares outstanding: 1.8 million.
- Market capitalization: USD 38.3 million.
- Year‑to‑date performance: down 18.29 % since the end of the previous month.
- 200‑day simple moving average: USD 25.19.
- 52‑week range:
- High – USD 33.63 (05 June 2026).
- Low – USD 18.50 (14 November 2025).
Recent Corporate Actions
On 19 October 2026, Precipio filed two Form 4 reports detailing equity awards to board members:
- David Seth Cohen
- Grant of 582 common shares in lieu of cash compensation for Q3 2026 service.
- Post‑grant ownership: approximately 55,800 shares.
- Christina Rizopoulos
- Grant of 122 common shares.
- Post‑grant ownership: approximately 5,750 shares.
These grants are part of the company’s standard incentive program for directors and were recorded during the current fiscal year. No other material actions were reported.
Contextual Market Activity
| Symbol | 24‑hour change | Current price (USD) | Market cap (USD mn) |
|---|---|---|---|
| TACT | +4.60 % | 4.80 | 44.9 |
| REKR | –9.37 % | 0.30 | 45.4 |
| KLRS | –4.50 % | 2.03 | 44.8 |
| SRTS | –0.36 % | 2.80 | 45.6 |
| IMA | –0.99 % | 4.11 | 45.9 |
Rekor Systems Litigation Update
Rekor Systems, Inc. (REKR) filed a current report on 19 October 2026 announcing a lawsuit against former director Viraj Mehta. The complaint, lodged in the Delaware Court of Chancery, alleges fiduciary breaches related to a December 2025 financing. The company seeks compensatory damages, disgorgement of director compensation, and other relief. No judgment has been issued; the outcome remains pending. The filing indicates Rekor’s ongoing governance review and notes potential implications for capital‑raising and shareholder interests.
Company Overview
Precipio, Inc. is a biotechnology firm in the Health Care sector. The company focuses on developing treatments for oncology, cardiology, neurology, and inherited diseases and offers clinical and research services to biopharmaceutical partners. Precipio’s operations are based in the United States, and its shares trade on the Nasdaq under the ticker PRPO. The company’s website is www.transgenomic.com .